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Summary Rhenium (I)-diselenother (Re-diselenoether) is a
water soluble metal-based compound, combining one atom of
rhenium and two atoms of selenium. This compound has been
reported to exhibit marked activities against several solid tu-
mor cell lines. We now disclose an improved synthesis of this
complex. The Re-diselenoether showed a potent inhibitory
effect on MDA-MB231 cell division in vitro, which lasted
when the complex was no longer present in the culture. Re-
diselenoether induced a remarkable reduction of the volume
of the primitive breast tumors and of the pulmonary metasta-
ses without clinical signs of toxicity, in mice-bearing a MDA-
MB231 Luc+ tumor, orthotopically transplanted, after a daily
oral administration at the dose of 10 mg/kg/d. Interestingly, an
antagonism was observed when cisplatin was administered as
a single i.p. injection 1 week after the end of the Re-
diselenoether administration. In an effort to gain insight of
the mechanisms of action of Re-diselenoether complex, inter-
action with 9-methylguanine as a nucleic acid base model was
studied. We have shown that Re-diselenoether gave both
mono- and bis-guanine Re adducts, the species assumed to
be responsible for the DNA intrastrand lesions.
Keywords Rhenium . Selenium . Breast cancer .
MDA-MB231 cell line . Bioluminescence
Introduction
Metal-based drugs have received increasing attention in recent
years. The use of metals is indeed very attractive, as they offer
unique spectrum of reactivity through ligand exchange and
redox processes that is not available in the more common
organic-based drugs. The discovery of the anticancer proper-
ties of cisplatin during the 1960s spurred the quest for alter-
native anticancer drugs with less side-effects. Beside platinum
analogues including platinum (II) and (IV) derivatives, other
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metals have been recently explored, such as gallium, rutheni-
um, iron, gold, titanium or palladium [1]. In this context,
rhenium-based drugs appeared as promising candidates for
clinical development. Over the past years a growing number
of studies have revealed the potential of Re organometallic
complexes as anti-cancer agents. A recent review has been
published with a particular emphasis on the cellular uptake
and the localization of the currently known Re organometallic
complexes as well as their potential mechanism of ac-
tion [2]. Among Re organometallic complexes, several
Re carbonyl complexes have been found to display cy-
totoxicity against breast cancer cell lines. For example, a
Re(tricarbonyl)pentylcarbonato compound able to fight triple
node negative human breast cancer cell lines has been de-
scribed [3]. Nevertheless, despite the design of very efficient
potent anti-cancer agents, very few in vivo studies have been
conducted on coldRe organometallic complexes. On the other
hand, it is noteworthy that some Se-based drugs have demon-
strated a selective cytotoxicity against cancerous cells [4–6].
The tumor-specific cytotoxic effects of Se, with special em-
phasis on cascades of cellular events induced by pharmaco-
logically active Se compounds have been recently reviewed
[7]. It appears that certain redox-activated Se compounds in-
duce complex cascades of pro-death signaling at pharmaco-
logical concentrations with superior tumor specificity, and that
the target molecules are often implicated in drug resistance.
With the aim to combine the antiproliferative properties of Re
with the unique apoptotic modulator properties of Se we have
recently designed the rhenium(I)-diselenoether complex 1 in
which a central Re atom is coordinated with two Se
atoms (Fig. 1). Complex 1 was shown to exhibit re-
markable cytotoxicity against MCF-7 breast cancer cell lines
[8]. The uptake and efflux of Re in malignant cells exposed to
complex 1 have been reported, together with evidence of the
incorporation of Re into the nucleus. Furthermore, tissue dis-
tribution of Re and Se after oral administration of 1 to mice
have been reported [9].
The purpose of the present paper was to report the
activity of Re-diselenother complex 1 (Fig. 1) in exper-
imental models of human breast tumor toward highly
metastatic MDA-MB231 cancer cells in culture, and in
MDA-MB231 Luc+ tumors transplanted in mice. The
interaction of 1 with 9-methylguanine is also described, pro-
viding evidence that interaction of 1 with DNA might
be involved in the mechanism of action of 1 at the
molecular level.
Material and methods
Chemical protocols
Although the published synthesis of complex 1 has proved
rather efficient, the elaboration of a key intermediate (com-
pound 4 in scheme 1) was somewhat problematic, since suf-
fering from a vexing lack of reproducibility. For that reason,
we have recently developed an alternative approach to key-
compound 4, which has proved perfectly reproducible. This
new protocol involved the alkylation of the disodium salt of
propane-diselenocyanate 2 with bromoacetic acid methyl es-
ter, giving diester 3, which was next saponified with lithium
hydroxide into diacid 4. Complexation of ReCl(CO)3 by
diselenoether 4, followed by sodium bicarbonate treatment
provided complex 1, as previously reported [8]. Likewise, to
study the possible interactions of the complex with DNA ba-
ses without competitive attack of the carboxylate appendages
on the Re atom, the corresponding dimethyl ester complex 5
was prepared by condensation of diselenoester 3 with
ReCl(CO)3 in 68 % yield.
Alternative synthesis of key intermediate Preparation of (3-
carboxymethylselanyl-propylselanyl)-acetic acid dimethyl es-
ter (compound 3): To a solution of 1,3-bis-selenocyanato-pro-
pane 2 (1.0 g, 3.96 mmol) in absolute ethanol (20 mL) was
added bromoacetic acid methyl ester (1.23 g, 8.0 mmol). The
mixture was stirred under nitrogen until complete dissolution.
Sodium borohydride (303 mg, 8.0 mmol) was then added in
one portion. The reaction mixture was stirred at room temper-
ature for 16 h. The white precipitate was filtered of on a
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Fig. 1 Chemical structure of complex 1
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Scheme 1 Synthesis of 1with optimized approach to key-intermediate 4.
Reagents and conditions, i: BrCH2CO2Me, NaBH4, EtOH, 16 h, 20 °C
(82 %); ii: LiOH.H2O, THF, MeOH, 16 h, 20 °C (85 %); iii: ReCl(CO)5,
THF, reflux, 16 h (72 %); iv: 2.0 equiv. NaHCO3, MeOH,H2O, 0 °C
(90 %); v: ReCl(CO)5, THF, reflux, 16 h (68 %)
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sintered glass funnel and the paint yellow filtrate was concen-
trated under reduced pressure to leave 3 as a pale yellow oil
(1.12 g, 82 %); 1H NMR (CDCl3): δ 3.72 (s, 6H, OCH3), 3.17
( s , 4H , CH 2CO2Me ) , 2 . 8 2 ( t , J = 7 . 2 Hz , 4H ,
SeCH 2CH2CH 2Se ) , 2 . 0 (qu in t , J = 7 .2 Hz , 2H ,
SeCH2CH2CH2Se).
Preparation of (3-carboxymethylselanyl-propylselanyl)-
acetic acid (compound 4) To a solution of compound 3
(692 mg, 2.0 mmol) in THF (3 mL) and methanol (1 mL)
was added a solution of LiOH.H2O (336 mg, 8.0 mmol) in
2 mL of water. The reaction mixture was stirred at room tem-
perature for 16 h and the solvents were removed under re-
duced pressure. 3 N HCl was added until pH=1, and the
mixture was extracted with ethyl acetate (3×15 mL). The
combined organic layers were dried over MgSO4 and concen-
trated under reduced pressure. The oily material was taken
into a small amount of CH2Cl2 and precipitate with petroleum
ether. The solid was filtered, washed with diethyl ether, and
dried under vacuum to give 540mg (85% yield) of compound
4, which was unequivocally identified by comparison with an
authentic sample.
Synthesis of dimethyl ester complex 5 Preparation of
r h e n a t e ( t r i c a r b o n y l c h l o r o [ 2 , 2 ′ - [ 1 , 3 -
propanediylbis(carbomethoxymethylseleno-)]]) (5): A mix-
ture of diselenoester 3 (216 mg, 0.62 mmol) and ReCl(CO)3
in THF (20mL) was heated at 60 °C for 16 h. Themixture was
cooled to room temperature and concentrated under reduced
pressure to leave crude 5. Purification by chromatography
over silica gel gave 5 as a colorless oil (278 mg, 68 %); 1H
NMR (C6D6): The presence of stereoisomers induced splitting
of most signals δ 3.61 (dd, J=14.1, 4.5 Hz, 1H), 3.42 (dd, J=
14.1, 6.9 Hz, 1H), 3.35–3.24 (m, 6H), 3.16–3.06 (m, 0.5H),
2.99 (d, J=13.8 Hz, 1H), 2.86 (m, 0.5H), 2.55–2.28 (m, 2 H),
1.5–1.2 (m, 4H).
Interaction of rhenium diseleno-ester 5 with 9-
methylguanine To a solution of complex 5 (139 mg,
0.21 mmol) in methanol (4 mL) was added dropwise a solu-
tion of AgBF4 (42 mg, 0.21 mmol) in methanol (1 mL). A
sticky precipitate formed immediately. The reaction mixture
was stirred at 15 °C for 16 h and filtered. The filtrate was
added to a solution of 9-methylguanine (35 mg, 0.21 mmol)
in 1:1 water: methanol mixture (24 mL). The reaction mixture
was stirred for 3 d at 15 °C and concentrated under reduced
pressure (1 mm Hg) at 20 °C. The obtained solid was washed
with methylene chloride to remove any trace of free
ligand and dried. Mass spectra analysis ESI (+) showed
four components: m/z=782.0 [C18H23N5O8ReSe2]
+;
616.9 [C12H16O7ReSe2]
+; 601.1 [C15H14N10O5Re]
+; 435.9
[C9H7N5O4Re]
+ . Ions m/z=782.0 and m/z=616.9 showed
the characteristic isotopic pattern of the ReSe2 fragment,
whereas ions m/z=601.1 and m/z=435.9 ions displayed a
more simple profile corresponding to a rhenium complex de-
void of the diselenoether ligand.
Morphological and inhibitory effects on MDA-MB231
breast cancer cells
Cell linesMDA-MB-231 (Passage No. 13) breast cancer cell
lines were kindly provided by Dr. S. Fraser and Pr. M.
Djamgoz at Imperial College, London. Cells were grown as
adherent monolayers in Dulbecco’s Modified Eagle Medium
(Sigma), supplemented with 5 % Fetal Bovine Serum
and phenol red. Cultures were maintained at 37 °C with
a humidified atmosphere containing 5 % CO2 and were
passaged using 0.25 % trypsin in DPBS (PAA) when they
reached 80 % confluency. Cell number was established
via haemocytometer count after dead cell exclusion
using trypan blue.
In vitro toxicityMDA-MB231 cells were seeded on 48-well
plates at 5×104 cells/well, allowed forming an adherent
monolayer overnight and then exposed to the indicated con-
centrations of Re-diselenoether complex for 48 h. Cells were
then washed and incubated with Re-diselenoether-free medi-
um for a further 48 h. The effects of Re on cell viability was
determined at the indicated time using haemocytometer count
of live cells under light microscopy and via flow cytometry.
Proliferation. Prior to Re treatment, MDA-MB231 cells at the
concentration of 1×106 /mL in PBS were labeled with 0.5 M
of violet dye (CellTrace violet Invitrogen) for 20 min at 37 °C.
The intensity of fluorescence of the violet dye was acquired on
an LSRFortessa flow cytometer (BD) and analyzed with
FlowJo version 9.3.1 (TreeStar, Ashland, OR, USA). Dose
responses over time were analysed using GraphPad Prism
software version 5.03 (GraphPad Software Inc.).
Animal study design: oral administration
of Re-diselenoether complex
This study was performed in Cellvax laboratory. In this study,
one of the objectives was to look for a synergism between
cisplatin and Re (I)-diselenoether [10]. Hormone-independant
breast cancer MDA-MB231 cells (origin: ATCC#HTB-26™),
transfected with the luciferase gene (Luc+) were orthotopically
implanted into the mammary gland (fat pad) in athymic nu/nu
nude mice (Charles River, France). With a cell viability of
about 97 %, 1.0×106 cells per mouse were injected in a vol-
ume of 50 μl/mouse. The animals were 5 to 6-week-old fe-
male, of about 20 g each, and specific and opportunistic path-
ogen-free. Theywere acclimatized for at least 7 days before the
initiation of the designed study. A total of 30 mice were used
for this study. Animals were housed in individual polyethylene
cages, in a climate and light-controlled environment. All
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animals were kept under environmentally controlled housing
conditions: lights on between 7:00 AM and 7:00 PM; temper-
ature inside of the animal facility strictly maintained at 21+
1 °C; relative humidity of 70 % throughout the entire study
period, and maintained in accordance with Cellvax approved
standard operation procedures (SOP) and with local Ethical
Committee approval. Animals were fed with commercially
available rodent food (Safe, Les Tremblats, Augy, France).
Water (sterilized water) was available ad libitum.
Animals were numbered and given a unique animal iden-
tification ear notch mark. Ethical manager. A Ph.D. and
Veterinary Doctor at Cellvax company assumed the function
of ‘Ethical Manager’ within this project. Experimental
groups: Three groups of 10 mice each for a total of 30 mice
were treated. Measurable mammary tumors were observed in
18 mice at day 9 after the inoculation of the tumor cells, while
no mammary tumors were observed in 12 mice. Groups were
then homogeneized to have 6 mice with a measurable tumor in
each group. Group 1: Cisplatin (CDDP) group: mice were
treated with CDDP as a single intraperitoneal (IP) injection
at a dose of 6 mg/kg on day 41 after the inoculation of the
tumor cells; Group 2: Re (I) - diselenoether complex group
(Re drug group): mice were daily orally treated with Re -
diselenoether complex at the dose of 10 mg/kg/24 h for
4 weeks, from day 9 to day 36 after the inoculation of the
tumor cells; Group 3: Re (I) - diselenoether complex and
CDDP group (combined drug group): mice were daily orally
treated with Re-diselenoether complex at the dose of
10 mg/kg/24 h for 4 weeks, from day 9 to day 36 after the
inoculation of the tumor cells (as in group 2) and then with
CDDP as a single intraperitoneal (IP) injection at a dose of
6 mg/kg on day 41 (as in group 1).
Oral administration of the Re compounds The Re treat-
ments were started on day 9 after the inoculation of the tumor
cells. They were orally administered in the food instead of
gavage, as it is a less stressful alternative to oral gavage [11].
Transwean was used to prepare capsules in which the Re (I)-
diselenoether was incorporated. The capsules were prepared
the day before treatment by mixing 1 g of transwean powder
(feed rodent form of powder mixed with water forms a sort of
jelly) and 1 mL of water. The mixture was then placed in the
wells of a 24-well plate and stored at 4 °C. The next day, the
capsules were removed from the mold with a spatula and then
cut into small pieces. Re drug at a dose of 10 mg/kg was
diluted in a volume of 50 μl and introduced into one of the
pieces of Bcapsule^ with a syringe, then that piece was placed
in the mouse cage. Once the capsule containing the treatments
were consumed normal food pellets were put into the cage
until evening. This mode of administration is simple and ef-
fective. The treatments were completely consumed with
no risk of overdose. Toxicity evaluation. Determination
of body weight was performed twice a week for each mouse.
Anti-tumor effect. The tumor growth was measured (tumor
length, width and volume) twice a week by using an
external caliper. The mean tumor volumes [MTV;
MTV + (SD); MTV + (SEM)] were estimated. The tu-
mor growth data was recorded for each individually identified
mouse. Tumor volume was calculated by using the following
formula: V=length x width2/2. An imaging by biolumines-
cence was performed in 2 mice of each group on days 44,
51 and 58 after the inoculation of the tumor cells. The mice
were selected to have comparable tumors on day 44.
Statistics Statistically evaluation of the antitumor effect was
assessed by ANOVA test (One way Anova on the ranks).
Results and discussion
Design and synthesis of Re-diselenoether 1
Critical to the antitumor activity of pseudo-symmetric com-
plex 1was the presence in its framework of a central inorganic
core, in which a heavy metal atom (Re) is coordinated with
two semi-metal atoms (Se). Although the canonical represen-
tation of 1 displayed high molecular symmetry, examination
of the 1H NMR spectrum clearly indicated the slow inversion
around the two selenium atoms and hence the slow chair-chair
interconversion of the six-membered metallacycle abolished
the apparent symmetry [8]. The chemical/biological consider-
ations which have governed the design of this three-metal core
scaffold were disclosed hereafter. A major interest of Re is
related to its very low mammalian toxicity; it has thus been
evoked that Re is Bone of the least toxic of the metallic
elements^. This low toxicity, quite surprising for a heavy met-
al, can be tentatively interpreted on the basis of its seven
degrees of oxidation state (1 to 7) that could authorize subse-
quent oxidative detoxification processes. Only few data exist
on the metabolism of Re compounds. However, a study of the
metabolism of [188Re(CO)3(carboxycyclopentadienyl)] in
mice revealed the high plasma stability of this Re compound
[12]. This study also suggested that the organometallic core of
this complex remained unchanged under biological environ-
ment. In full agreement with this assertion, the Re compound
was essentially excreted as glycine conjugate via the renal
route, without further metabolism.
Regarding the presence of two Se atoms in complex 1, it
should bementioned that, fueled by decades of animal studies,
Se could significantly reduce the incidence of cancer. This
topic is now an area of intense worldwide study [13].
Nevertheless, although inorganic Se has been shown to inhibit
carcinogenesis, there is a concern about toxicity, since chronic
feeding of inorganic Se (e.g., selenites or selenates) at levels
of> 5 ppm is toxic in rodents. However, on the basis of the
pioneering work of El-Bayoumy et al. [14–16] and Sanmartin
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et al. [17–19], a series of synthetic Se compounds have been
elaborated, in which the Se atom is connected to two carbon
atoms, as in complex 1. These compounds have proved nota-
bly more potent and much less toxic than the inorganic coun-
terparts. In contrast to Re compounds, the metabolism of Se
compounds in mice is well-documented. It was found that Se
compounds which included the RCH2SeCH2R pattern in their
structure, such as complex 1, were first cleaved via the trans-
selenation pathway into RCH2SeH metabolite that, in turn
was converted into H2Se through the β-lyase dealkylation
reaction. Both H2Se and CH3SeH are thought to be pivotal
metabolites in Se-mediated cancer chemoprevention [7]. A
last comment should be made on the design of 1. Since the
advantage of all ionic compounds over neutral species is their
improved solubility in water, which markedly facilitates their
application in biological systems, precursor 2was ornamented
at the Se-levels with two acetic acid moieties [2→4]. At the
last step of the synthesis the two carboxylic acid functions
were ultimately converted into water-soluble disodium salt 1
(Scheme 1).
The new procedure of synthesis of compound 1 was sim-
ple, reproducible, giving a stable product easily authenticated
through its IR spectrum. The presence of a d6 fac-[Re(CO)3]
+
moiety in complex 1 could explain its high chemical stability.
This complex is amphiphilic, soluble in water, and then easy
to administer. It also possesses lipophilic properties that allow
a facile diffusion across cell membranes and a good
biodistribution.
Interaction of Re-diselenoether complex
with 9-methylguanine
Extensive studies with many [Re(CO)3] complexes indicate
that their cytotoxicity is due to the formation of 1,2-intrastrand
adducts e.g., between the N-7 atom of two adjacent guanine
residues in DNA, in a fashion similar to cisplatin. Likewise,
Re accumulation in cell nucleus treated with Re-diselenoether
1 suggested a possible interaction with nucleic acids [9]. To
probe such binding with complex 1, we have investigated the
reaction of 5 with 9-methylguanine (9-MeG) as simple surro-
gate of the guanine base in DNA. Dimethyl ester 5was used as
surrogate of complex 1, since the presence of two sodium
carboxylates in latter compound was clearly incompatible
with the coupling conditions. Indeed, Alberto and Zobi had
previously reported that the [Re(CO)3]
+ cation bound to 9-
MeG to give mono or bis-adducts [20, 21]. Thus, reaction of
5 with silver fluoroborate gave the corresponding cation
which was further reacted with 1 equiv. of 9-MeG in
methanol/water mixture. Analysis of the obtained mixture by
mass spec t romet ry ind ica ted tha t mono-adduc t
[Re(CO)3(C9H16Se2O4).9-MeG]
+ BF4
− (A, Fig. 2) was indeed
formed as a minor component (10–15 %). Interestingly, the
major product turned out to be the bis-adduct [Re(CO)3(9-
MeG)2(H2O)]
+ BF4
− (B), previously observed by Alberto
and Zobi. The isotopic profiles of both ions are in full agree-
ment with the predicted patterns for the proposed molecular
formulas (Fig. 2). In addition, the infrared spectrum of B re-
vealed characteristic CO vibrations at 2027, 1915 and
1895 cm−1 previously reported for this 9-MeG bis-adduct
[20]. These observations clearly indicated that the bis-
selenoether ligand could be easily displaced by nucleic acid
bases to provide guanine bis-adducts, suggesting that the Re-
diselenoether complex 1 would be able to form intrastrand
lesions. We may hypothesized that in biological medium, fol-
lowing initial aquation, the intermediate Re cation is able to
react with nucleic acid bases in nucleus to give mono-adduct
(Ion A, Fig. 2; Ion A, Supplementary Fig. 1). The constraint
nature of the latter probably facilitated the exchange of the
weakly chelating diselenoether ligand by water to give a very
reactive ion (Ion D, Supplementary Fig. 1). Finally, a second
nucleic acid base addition can easily take place to give 1,2-
intrastrand adducts (Ion B, Fig. 2; Ion B, Supplementary
Figure 1, whereas the liberated seleno ligand would probably
diffuse throughout the cell.
Antitumor effect in vitro of the Re-diselenoether complex 1
It was earlier shown that MCF-7 breast malignant cells were
more sensitive to the Re-diselenoether complex 1 than A 549
lung cancer cells and HeLa cervix carcinoma cells [9]. We
therefore investigated malignant cells derived from a human
breast carcinoma, the hormone-independent MDA-BB231
cells for the morphological and inhibitory effects of the Re-
diselenoether complex.
In the presence of a low concentration of Re (I)-
diselenoether complex (10 μM), modifications in cell shape
and morphologywere clearly visible (Fig. 3a) when compared
to untreated cells. These cellular alterations corresponded to a
reduction in size and a loss of adherence indicating that treated
cells were no longer proliferating and possibly included apo-
ptotic cells. Further analysis was performed using Flow cy-
tometry where Forward Scatter (FSC) and Side Scatter (SSC)
parameters correspond tomeasurements of cell size (FSC) and
granularity (SSC) (Fig. 3b). Cellular and nuclear debris gen-
erated by dead cells were characterized by low FSC/SSC
values (<30 K) and excluded from the live gate. Upon 48 h
exposure to Re, only 65.1% of Re-treated cells were identified
as alive compared to 92.1 % in the untreated condition. This
heterogeneous population included cells of low FSC, indica-
tive of non-proliferative cells, and cells of high SSC, indica-
tive of granular apoptotic cells, which supported the micro-
scopic observations (Fig. 3a).
One of the hallmarks of cancer cells is their dysregulated
proliferation. To further evaluate the effect of the Re complex
on tumor cell ability to proliferate, MDA-MB231 cells were
cultured for 48 h in the presence of 10 μMof Re complex, and
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for an additional 48 h in Re-free medium. A cell trace violet
dye was used to label the cells prior exposure to Re and fluo-
rescence intensity was analysed by flow cytometry (Fig. 4a).
Labeled cells at d0 showing maximal fluorescence intensity
(shaded red histogram) and unlabeled cells (shaded blue his-
togram) were used as controls. As expected, untreated MDA-
MB231 cells showed cell divisions characterized by a reduc-
tion in violet dye fluorescence intensity at d2 and an even
greater reduction at day 4 (upper panel). Interestingly,
MDA-MB231 cells treated for 48 h with Re showed a reduc-
tion in fluorescence intensity at d2, yet to a lesser extent than
untreated cells (lower panel). Most importantly, there was no
further reduction at d4 indicating no further proliferation.
These data show that the Re complex had a negative impact
on cell division within the 48 h of culture; this inhibition was
not reversed by the absence of Re in the culture beyond 48 h.
Cell division was also quantified by standard cell counts at
d2 and d4 of culture with 10 and 50 μM of Re complex
(Fig. 4b). Exposure to a concentration of 50 μM of Re com-
plex had a striking effect on cell proliferation showing a total
inhibition of cell division as early as 48 h which lasted after
removal of the Re complex. In line with the flow cytometry
experiment (Fig. 4a), the lower concentration of 10 μMof Re-
drug was effective to slow down cell proliferation within 48 h
of culture and prevented the cells to proliferate further
beyond that time point. Altogether, these data show that
the Re-diselenoether complex is a potent inhibitor of
tumor cell division at low concentration and that this
effect is sustained even when the complex is no longer present
in the culture.
Potential targets of the Re-diselenoether complex 1
It has been reported that Re-based drugs could target more
specifically the malignant cells than the healthy cells [2, 22].
On the other hand, it is noteworthy that some Se-based drugs
have demonstrated a selective cytotoxicity against cancerous
cells [4–6]. The tumor-specific cytotoxic effects and the cas-
cades of cellular events induced by the major groups of phar-
macologically active Se compounds have been reviewed [7].
It is clear that certain redox-active Se compounds induce com-
plex cascades of pro-death signaling at pharmacological con-
centrations with superior tumor specificity, and that the target
molecules are often implicated in drug resistance. This review
also emphasized on the chemotherapeutic applications of Se
with multi-target attacks on tumor cells, and moreover on the
Fig. 2 Observed (bottom) and
predicted (top) isotopic patterns
of 9-methylguanine mono-adduct
ion [Re(CO)3(C9H16Se2O4).
9-MeG]+ (a) and bis-adduct ion
[Re(CO)3(9-MeG)2(H2O)]
+ (b)
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great pharmacological potential of Se for the treatment
of resistant cancers.
The Re capture was previously studied in the nucleus of
three human breast cancer cells [9]: MCF-7s (sensitive cells),
MCF-7R (resistant cells) and MCF-7 MDR (multidrug resis-
tant cells) were exposed to the Re-diselenoether drug at the
dose of 400 μM for 48 h (uptake), followed by a post-
exposure period of 48 h (efflux). The next intra-nuclear Re
concentrations (μM/106 cells) were recorded: MCF-7 s: 0.08
(uptake), 0.25 (efflux), MCF-7R: 0.25 (uptake), 0.12 (efflux)
and MCF-7 MDR: 0.15 (uptake), 0.09 (efflux). Regarding the
uptake of Re, the concentration in the nucleus was less impor-
tant in the MCF-7s sensitive cells than in the other cell types.
However, inMCF-7R and inMCF-7MDR, which are MCF-7
cells with an acquired resistance to cytotoxic agents, the nu-
cleus concentration in Re notably decreased after the post-
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and cells with decreasing amount
of violet dye at d2 (green) and d4
(orange) due to a dilution of the
violet dye upon cellular division.
Data are representatives of 3
independent experiments. b
Average fold increase in cell
number over 4 days of culture in
the presence of 0, 10 or 50 μM of
Re complex. Data represents the
mean±SEM values pooled from 2
independent experiments
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Fig 3 a Lightmicroscopy images
(5x objective) and (b) Flow
cytometry dot plots comparing
MDA-MB231 cells that have
been exposed or not to 10 μM
of the Re-diselenoether complex
for 48 h
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exposure period, indicating an efflux of Re out of the nucleus.
This observation is of critical importance regarding the thera-
peutic protocol. Indeed, with the aim of overcoming the dra-
matic consequences of a Re efflux in these nuclei, it appeared
necessary to maintain a continuous exposure of the malignant
cells to the drug; this may be achieved through a daily oral
administration.
Antitumor effect of the rhenium-diselenoether 1
in MDA-MB231 tumor-bearing mice
It is known that liposomal rhenium cluster compounds poten-
tiate a platinum-based chemotherapy [22–25]. For that reason,
we decided to investigate a potential synergism between cis-
platin and the Re-diselenoether complex in our experimental
model with transplanted MDA-MB231 Luc+ human breast
tumor in mice. Three groups were thus compared: Group 1,
treatment by cisplatin (control); group 2, treatment with Re-
diselenoether complex; group 3, treatment by Re-
diselenoether complex + cisplatin. Re-diselenoether complex
showed remarkable antitumor effects versus cisplatin-based
chemotherapy in mouse model of breast cancer. The volume
of the primitive tumor was remarkably reduced inmice treated
with Re-diselenoether complex versus those treated by cisplat-
in, taken as a control group (p=0.0006). Results are depicted
in Fig. 5 and in Table 1 (Supplementary Table 1).
A first divergence between the three curves was observed
on d16, that is to say, 2 weeks after tumor grafting. In group 1
(mice treated with a single administration of cisplatin on d41),
a regular tumor volume increase was recorded at the d16-d67
interval, with a final volume reaching up to 140 mm3.
Regarding group 2 (mice treated daily with the Re drug from
d9 to d36), a plateau was observed at the d16-d44 interval,
with a tumor volume not exceeding 20 mm3, followed by a
complete regression of the tumors at the d47-67 interval. In
group 3 (mice treated with the Re drug according to group 2
protocol, combined with a single administration of cisplatin
on d41), the tumor volumes approximately matched those of
group 2 until cisplatin administration, followed by a rapid
increase until d67, with a final volume reaching up to
180 mm3. These observations deserve the following com-
ments. The absence of any significant inflexion in the profile
of curve 1 after cisplatin administration clearly reflected a lack
of antitumor activity of this Pt-drug toward MDA-MB231
tumor-bearing mice with this schedule of treatment. By con-
trast, the profile of curve 2 revealed a nearly immediate anti-
tumor effect of the Re drug, and a complete cure of the tumors
after a one-month drug exposure, followed by a post-exposure
period of 2 to 3 weeks. Examination of the profile of curve 3 is
of peculiar interest regarding the mechanistic aspect of Pt-
drugs and Re-drugs. Indeed, to our great surprise, a deleterious
effect was observed when Re-drug 1 was co-administered
with cisplatin, namely a dramatic collapse of the antitumor
activity. This phenomenon can be interpreted on the basis of
the binding modes of these metal-based drugs to DNA nucle-
otides which suggest that a Pt-drug could irreversibly displace
a Re-drug from a pre-existing DNA-adduct. This assertion
was reinforced through the consideration that both Re-drugs
and Pt-drugs target the same recognition sites in DNA bases,
exemplified by the N7 center of guanine.
Bioluminescence imaging in mice The imaging by biolumi-
nescence (Prof. Valérie Rouffiac, Institut Gustave Roussy,
France) illustrated the effects of Re (I)-diselenoether complex
on the tumor activity (Fig. 6). In the group of the two mice (S1
and S2) treated with the Re drug, the tumor was visible on the
first imaging on day 44 after the inoculation of the cancer cells
(S1-S2, 11/03 images). On day 51 (18/03), the tumor has
disappeared in mouse S2. On day 58 (25/03), there was no
detectable tumor in the two mice, indicating a complete re-
gression of the tumor activity, an effect sustained a long time
after the interruption of the treatment with the Re-
diselenoether complex (end of the treatment on day 36 after
the inoculation of the cancer cells).
Incidence of Re-diselenoether complex on pulmonary me-
tastases The pulmonary metastases could be evaluated in 9
mice of each group (one mouse in each group died before day
Fig. 5 Volume of the tumors after
the inoculation of the cancer cells.
Group 1: treatment by cisplatin
(control); group 2: treatment with
Re-diselenoether complex; group
3: treatment by Re-diselenoether
complex + cisplatin
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42 and the number of pulmonary metastases was not mea-
sured). Seven suffering mice were sacrificed on day 65 (two
from group 1, one from group 2 and one from group 3:
they all had pulmonary metastases). All other mice were
sacrificed on day 67, corresponding to the end of the
study. Finally, the presence of pulmonary metastases
was noted in 9/9 mice in group 1; 5/9 in group 2 and
7/9 in group 3, with a mean number of metastases of
7.22±2.47 in group 1; 3±1.2 in group 2 and 3.57±0.90
in group 3, as represented in Fig. 7. The number of
metastases was significantly greater in group 1 versus
group 2 (p<0.05) and in group 1 versus group 3
(p<0.05), but there was no significant difference in group 2
versus group 3.
Evaluation of the toxicity of Re-diselenoether complex
There was no sign of clinical toxicity in all groups according
to the body weight of the mice, as depicted in Fig. 8. There
was a death, but one in each group, between days 26 and 39
before the injection of cisplatin, that could be probably attrib-
uted to the pulmonary metastases (an autopsy was performed
in 2 mice, revealing a great number of metastases). Thus, the
dose of 10 mg/kg/24 h of Re-diselenoether appeared to be
well-tolerated.
Biodistribution of Re-diselenoether complex in mice The
efficacy of the complex has been established in the animal
experiment at a non-toxic dose of 10 mg/kg/d for 4 weeks, both
on the primitive tumors and on the metastases. The
biodistribution of Re and Se has already been published at this
oral dose of 10mg/kg/d versus 40mg/kg/d of Re-diselenoether,
and it was shown that the oral administration allows a good
tissue uptake of Re and Se with a dose-effect [9]. Mice were
treated with Re-diselenoether at the dose of 10 mg/kg (corre-
sponding to 3.3 ppm in Re and 2.8 ppm in Se), and 40 mg/kg
(13 ppm in Re and 11 ppm in Se), once-a-day for a period of
4 weeks. The distribution study revealed a Re concentration in
the liver of 7.1 μmol/kg wet tissue (1.3 ppm) at the dose of
10 mg/kg and 19.8 μmol/kg wet tissue (3.4 ppm) at the dose of
40 mg/kg. Compared to the liver, lower concentrations were
recorded in the kidney, namely 4.3 μmol/kg wet tissue
(0.8 ppm) at the dose of 10 mg/kg and 8.8 μmol/kg wet tissue
(1.6 ppm) at the dose of 40 mg/kg. Regarding Se, the following
concentrations (corrected from the essential Se found in the
tissues of untreated mice) were recorded : in the liver,
12.9 μmol/kg wet tissue (1.0 ppm) at the dose of 10 mg/kg,
31.1 μmol/kg wet tissue (2.5 ppm) at the dose of 40 mg/kg; in
the kidney, 7.0 μmol/kg wet tissue (0.5 ppm) at the dose of
10 mg/kg and 8.8 μmol/kg wet tissue (0.7 ppm) at the dose of
40 mg/kg. These results deserve the following comments. A
clear dose-effect of the drug was observed. Indeed, a 4-fold
increase of the administered dose of Re-drug 1 (from 10 to
40 mg/kg/d) resulted in a 2.8-fold increase of the Re concen-
tration in the liver and a 2.0-fold increase in the kidney. On the
other hand, the Se/Re molar ratios in the liver were 1.8 at the
dose of 10 mg/kg and 1.6 at the dose of 40 mg/kg. These ratios
are quite close to the 2.0 Se/Re ratio found in the drug (two
Fig. 6 Imaging by
bioluminescence in two mice
(S1 and S2) treated by
Re-diselenoether complex
(from day 9 to day 36), on days 44
(11/03), 51 (18/03) and 58 (25/03)
Fig. 7 Pulmonary metastases. Group 1: mice treated by cisplatin, group
2: mice treated by Re (I) diselenoether complex, group 3: mice treated by
Re (I)-diselenoether complex + cisplatin
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atoms of Se and one atom of Re per molecule). This observa-
tion suggests that the drug might be stored in the liver, more or
less as it stands. However, in comparison with the liver, lower
Se/Re ratios were recorded in the kidney (1.6 at the dose of
10 mg/kg and 1.0 at the dose of 40 mg/kg). These ratios re-
vealed, as expected, a notable excretion/metabolization of the
drug at the kidney level.
Mechanisms of action of diselenoether complex 1 As both
Re and Se are well taken up by tissues, it is possible to con-
sider that these two elements will contribute to the antitumor
effects by the combination of their different mechanisms of
action. The main biological effects of Re are the formation of
adducts (single or double strands) with proteins or DNA.
These interactions have been extensively studied by Alberto
[20, 21, 26] and Zobi [27]. Re can bind to DNA adenine
through the N1, N6 positions [28] or to guanine through the
N7 position [29, 30], resulting in Re/nucleotide 1:1 or Re/
nucleotide 1:2 adducts. Reaction of Re-diselonether 5 with
9-methylguanine used as a simple model of DNA bases clear-
ly established its ability to produced Re/nucleotide 1:1 or Re/
nucleotide 1:2 adducts. In contrast to cisplatin, binding of Re
drugs to one or two bases is reversible, the Re-adducts having
proved less stable than Pt-adducts. In fact, the formation of
octahedral Re-adducts may be disfavored since they are gen-
erally more bulky and more sterically crowded than square-
planar Pt-adducts. The possibility to administer the Re-
diselenoether as a continuous oral administration offers an
advantage upon cisplatin, which generally needs to be admin-
istered through a single injection.
Although the anti-carcinogenic properties of Se are now
well established, the modes of action of this element are still
a subject of discussion, since they are very complex and not
fully understood. However, we can emphasize on the mecha-
nisms of action of Se on redox potential status, inflammation,
immunity and cell signaling pathways including the conse-
quences on cell apoptosis, DNA repair and metal detoxifica-
tion, angiogenesis, metastasis, and finally the effects on the
tumor growth.
Among the mechanisms of action of Se, its effects on the
oxidative system are perhaps the most important. Se is mainly
an anti-oxidant, via the selenoproteins, such as glutathione
peroxidase (GPx) and thioredoxine reductase (TrxR). In fact,
the existence of a systemic pro-oxidant status in patients with
breast cancer is well-established [31], depending on the stage
of the disease [32] and on the molecular subtype [33]. A single
systemic profile was found in patients with triple negative
breast cancer with higher NO levels among subtypes [33].
An other antioxidant, the superoxide dismutase (SOD), has
also been proposed to fight against cell proliferation [34].
Ovarian cancer patients resistant to treatments by
carboplatin/paclitaxel have a lower level of antioxidant re-
sponse activation compared to sensitive patients [35], and to
restore the oxidative status could increase the efficacy of an-
ticancer cytotoxic drugs. By contrast, the common cytotoxic
agents are pro-oxidant drugs, like paclitaxel and doxorubicin
[36]. In this respect, high concentrations of Se may produce
reactive oxygen species (ROS) and lead to apoptotic cell death
by inducing oxidation and cross-linking of protein thiol
groups essential for cell survival [37]. According to Jamier
et al. [38], Se-based agents could turn the oxidizing redox
environment present in certain cancer cells into a lethal cock-
tail of reactive species, that push these cells over a critical
redox threshold and ultimately kill them through apoptosis.
This kind of toxicity is highly selective: healthy cells remain-
ing largely unaffected, since changes to their naturally low
levels of oxidizing species produce little effect. The balance
between pro-oxidative and anti-oxidative effects of Se com-
pounds is still unclear, but it is obvious that the redox potential
of cancer cells needs to be taken into account to evaluate the
treatments by Se compounds. Avery interesting display thiol-
proteomics approach to characterize global redox modifica-
tion of proteins by Se has been proposed by Park et al. [39].
As a second mechanism of action, Se, mainly as
selenoproteins, plays an important role in inflammation
[40, 41]. There is a strong interaction between inflammation
and cancer, and Pt-drugs have even been designed with the
aim of targeting NF-kappa B signaling pathways [42]. Se
Fig. 8 Mean weight of the mice
after the inoculation of the cancer
cells. Group 1: treatment by
cisplatin (control); group 2:
treatment with Re-diselenoether
complex; group 3: treatment
by Re-diselenoether
complex + cisplatin
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compounds could have an impact on the inflammatory status
through the inactivation of NF-kappa B [43, 44]. The interac-
tions between cancer stem cells (CSC) and inflammation are
also of a great importance [45] for the development of cancer
and its resistance to therapeutic agents. Due to its effect on
inflammation, we could expect a role of the Re-diselenoether
complex in the growth and activity of CSC.
Studies with Se-compounds indicated that Se may also have
positive effects on immune response [46–48], and more specif-
ically on the activity on natural killer (NK) cells [49–51].
Methylselenol, which is the active metabolite of organic Se
compounds, has already been shown to regulate the expression
of NKG2D ligands by MDA-MB231 and MCF-7 cells [52].
These ligands are involved in the recognition of the malignant
cells by NK cells [53–58]. Selenoproteins also mediate T cell
immunity through an antioxidant mechanism [59]. Se plays
also an important role as an anti-inflammatory agent by tightly
regulating the expression of pro-inflammatory genes in
immune cells [60].
The role of Se compounds on signaling pathways involved
in the development of cancer has become a very attractive area
of research. Se-compounds are thought to modulate several
kinases. The PI3K/AKT pathway appears as a common target
for Se-compounds, but they may modulate different kinases at
the same time and their effectiveness depends on the genetic
background of the tumor cells [61, 62]. All the Se-compounds
did not exhibit kinase inhibitory activity. The type of kinase
inhibition greatly depends on the Se derivative. The kinases
modulated by S- and Se- derivatives include MAP, ERK,
JNK, Akt, Cdc2, Cyclin B1 and Cdc25c amongst others
[17]. Therefore, there is a great need for testing the Re-
diselenoether complex on different tyrosine and serine/
threonine kinases, especially in breast cancer cell lines.
Due to the molecular and biological effects of Se and
selenoproteins, there is an expected benefit in cancer patients,
not only on the primitive malignant tumor growth, but also on
angiogenesis [63, 64] and metastasis [65]. However, the exact
schedule of treatment needs to be clarified for each cancer
disease, with the help of different markers that remain to be
better identified. Plasma Se levels, which have already been
investigated in a cohort of breast cancer patients [66], could be
useful tomonitor the therapy.Whatever the modes of action of
these elements, one can argue that there existed a synergistic
effect between Re and Se partners accounting for the remark-
able, promising antitumor activity of Re(I)- diselenoether
complex, already patented in Europe [67].
In summary, Re-diselenoether complex is a promising new
metal-based anticancer drug for the treatment of patients with
metastatic breast cancer. It proved to efficiently reduce tumor
cell division in vitro at a low concentration of 10 μM. It may
be orally administered, and the recommended dose is a non-
toxic dose of 10 mg/kg/d for a treatment of at least 4 weeks.
The efficacy may result from the activity of both Re and Se on
key targets of the cancer cells and their microenvironment.
Among the mechanisms of action, we confirmed the effects
on DNA, due to the Re atom. The effects on the immune
system, the redox status, the inflammation and cell signaling
pathways attributed to the Se component will be investigated
in further studies with models of hormone-independent
(MDA-MB231) and hormone-sensitive (MCF-7) metastatic
breast cancer.
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